These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11248 related articles for article (PubMed ID: 12054066)

  • 1. Cancer vaccines, a critical review--Part II.
    Mitchell MS
    Curr Opin Investig Drugs; 2002 Jan; 3(1):150-8. PubMed ID: 12054066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer vaccines, a critical review--Part I.
    Mitchell MS
    Curr Opin Investig Drugs; 2002 Jan; 3(1):140-9. PubMed ID: 12054065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
    Holmberg LA; Sandmaier BM
    Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma.
    Monzavi-Karbassi B; Hennings LJ; Artaud C; Liu T; Jousheghany F; Pashov A; Murali R; Hutchins LF; Kieber-Emmons T
    Vaccine; 2007 Apr; 25(16):3022-31. PubMed ID: 17303294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic HER-2/neu peptides as tumor vaccines.
    Baxevanis CN; Sotiriadou NN; Gritzapis AD; Sotiropoulou PA; Perez SA; Cacoullos NT; Papamichail M
    Cancer Immunol Immunother; 2006 Jan; 55(1):85-95. PubMed ID: 15948002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: Theratope, Biomira Inc.
    Morse MA
    Curr Opin Mol Ther; 2000 Aug; 2(4):453-8. PubMed ID: 11249777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic cancer vaccines.
    Morris LF; Ribas A
    Surg Oncol Clin N Am; 2007 Oct; 16(4):819-31, ix. PubMed ID: 18022546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccination against tumors.
    Prud'homme GJ
    J Gene Med; 2005 Jan; 7(1):3-17. PubMed ID: 15538731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of HER-2/neu-specific vaccines.
    Murray JL; Przepiorka D; Ioannides CG
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):71-5; discussion 92-100. PubMed ID: 11236031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.
    Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM
    Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
    Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
    J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
    Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies and vaccines--hope or illusion?
    Jäger D; Knuth A
    Breast; 2005 Dec; 14(6):631-5. PubMed ID: 16242931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
    Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
    Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 563.